Introduction {#section5-1756284818820438}
============

Irritable bowel syndrome (IBS) is a chronic functional bowel condition, which is characterized by abdominal pain and altered bowel habits in the absence of an organic disease.^[@bibr1-1756284818820438]^ Conventional treatment for IBS has been oriented towards the symptomatic management of diarrhea, constipation, pain, cramping and bloating.^[@bibr2-1756284818820438]^ Exercise and dietary manipulation, such as low FODMAP diet, are key first-line treatment options.^[@bibr3-1756284818820438][@bibr4-1756284818820438]--[@bibr5-1756284818820438]^ The United Kingdom (UK) National Institute for Health and Clinical Excellence (NICE)^[@bibr6-1756284818820438]^ and the World Gastroenterology Organization global guideline^[@bibr7-1756284818820438]^ recommend antispasmodics as first-line therapy for relieving global IBS symptoms. However, antispasmodics may lead to adverse events, including dry eyes and mouth, and blurred vision.^[@bibr8-1756284818820438]^ An antidiarrheal, loperamide, is also recommended in relieving diarrhea among IBS patients in NICE guidelines,^[@bibr6-1756284818820438]^ but it may result in potential side effects, such as dizziness and vomiting.^[@bibr9-1756284818820438]^ Antidepressants are suggested to be effective in global symptom relief among IBS patients, yet adverse events, public acceptability and their availability in the primary care setting have restricted their use.^[@bibr10-1756284818820438]^ Other commonly used strategies for managing diarrhea (e.g. probiotics) and constipation (fiber and polyethylene glycol) are ineffective for reducing overall and abdominal symptoms.^[@bibr10-1756284818820438],[@bibr11-1756284818820438]^

In the United States (US), only one-third of IBS patients show satisfaction with their current therapies.^[@bibr12-1756284818820438]^ Lack of effectiveness and associated adverse effects are common reasons for dissatisfaction.^[@bibr12-1756284818820438]^ In view of these treatment gaps, some patients turn to traditional, complementary and integrative medicine (TCIM). In Australia, a population-based survey showed that about 21% of IBS patients had consulted a TCIM practitioner.^[@bibr13-1756284818820438]^ In the UK, the prevalence of TCIM use among IBS patients attending outpatient specialist clinics was as high as 50%.^[@bibr14-1756284818820438]^ In the US, a cohort study among functional bowel disorder patients suggested that the incidence of TCIM use was 35% over a 6-month period.^[@bibr15-1756284818820438]^ In China, the use of Chinese medicine is prevalent among chronic disease patients.^[@bibr16-1756284818820438],[@bibr17-1756284818820438]^ Acupuncture and related therapies, as well as Chinese herbal medicine, have been extensively used for treating functional gastrointestinal disorders, including IBS.^[@bibr18-1756284818820438],[@bibr19-1756284818820438]^

Despite their wide usage, existing clinical evidence on acupuncture is conflicting. In a Cochrane review of two trials, needle and sham acupuncture were found to be of similar effect in improving IBS symptoms.^[@bibr20-1756284818820438]^ However, another meta-analysis showed that needle acupuncture provided stronger effects in IBS symptom relief than pharmacological therapies.^[@bibr21-1756284818820438]^ The three other systematic reviews (SRs) suggested that needle acupuncture plus moxibustion was superior to pharmacological therapies for reducing IBS symptoms.^[@bibr22-1756284818820438][@bibr23-1756284818820438]--[@bibr24-1756284818820438]^ Inconsistent evidence summarized in different SRs makes it difficult to conclude whether acupuncture and related therapies may be used as a complement to, or an alternative treatment option for IBS.

In order to address the uncertainty described above, we conducted an overview of SRs to synthesize and critically appraise all clinical evidence on the comparative effectiveness of acupuncture and related therapies used either alone, or as an add-on to other treatments, compared with other IBS treatments using a network meta-analysis (NMA) approach.^[@bibr25-1756284818820438]^

Methods {#section6-1756284818820438}
=======

Inclusion criteria {#section7-1756284818820438}
------------------

The definition of an SR was adopted from the most updated Cochrane Handbook (version 5.1.0), which defines an SR as an 'attempt to identify, appraise and synthesize all the empirical evidence that meets prespecified eligibility criteria to answer a given research question.'^[@bibr26-1756284818820438]^ Based on the definition, we judged a publication as an SR if it answered a research question by searching at least two electronic databases.^[@bibr27-1756284818820438]^

To be included in this overview, SRs had to be in either the English or Chinese language and satisfy the criteria for participants, intervention, comparisons and outcomes of interest listed below. Individual randomized controlled trials (RCTs) were then retrieved from eligible SRs, which is a common approach used in NMA.^[@bibr28-1756284818820438]^

Participants {#section8-1756284818820438}
------------

Patients diagnosed with IBS by any defined diagnostic criteria were included. The Manning criteria,^[@bibr29-1756284818820438]^ the Kruis criteria,^[@bibr30-1756284818820438]^ Rome I,^[@bibr31-1756284818820438]^ Rome II,^[@bibr1-1756284818820438]^ and Rome III criteria^[@bibr32-1756284818820438]^ as well as the recent Rome IV criteria^[@bibr33-1756284818820438]^ were considered as eligible, among other commonly used clinical criteria in China. There was no restriction on patients' other characteristics or comorbidities.

Intervention and comparisons {#section9-1756284818820438}
----------------------------

In this overview of SRs, 'acupuncture and related therapies' was defined as single or combined use of needle acupuncture, moxibustion, electroacupuncture, periorbital acupuncture and catgut embedding ([Table 1](#table1-1756284818820438){ref-type="table"}).^[@bibr34-1756284818820438][@bibr35-1756284818820438][@bibr36-1756284818820438]--[@bibr37-1756284818820438]^ Acupuncture and related therapies including the single or combined use of these acupuncture modalities were considered eligible for this overview. SRs with studies providing any type of control treatments were considered, including conventional pharmacological and nonpharmacological treatments, as well as Chinese herbal medicine. Regardless of control treatment, to be eligible a trial must allow the estimation of net effect of acupuncture and related therapies.

###### 

Definitions of acupuncture and related therapies in this overview of systematic reviews.

![](10.1177_1756284818820438-table1)

  ------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Needle acupuncture        Needle insertion into acupuncture points, followed by manual manipulation such as lifting and thrusting, twirling and rotating, or a combination of the two. The function of needling is believed to promote Qi (the vital energy) in the meridians in order to produce its therapeutic effect.
  Moxibustion               A method in which a moxa herb is burned above the skin or on the acupuncture points. It can be used a cone, stick, loose herb, or applied at the end of the acupuncture needles. The purpose of moxibustion is to alleviate symptoms by applying heat to the acupuncture points.
  Electroacupuncture        A modern acupuncture technique used with manual acupuncture, where needle is attached to a trace pulse current after it is inserted to the selected acupoint for producing synthetic effect of electric and needling stimulation.
  Periorbital acupuncture   A form of needle acupuncture in which the acupoints around the eyes are used.
  Catgut embedding          An acupuncture technique which involves weekly infixing of surgical chromic catgut sutures into the subcutaneous tissue of acupoints located at the abdomen, extremities and the back with a specialized needle under aseptic precautions.
  ------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Outcome of interest {#section10-1756284818820438}
-------------------

To be included in an NMA, trials should include at least one of the following outcomes: (1) IBS symptom improvement, measured with either global or individual symptom scores; or (2) proportion of patients reaching satisfactory relief of global or individual symptoms. These outcomes were chosen based on current reviews on the primary endpoints of IBS clinical trials.^[@bibr38-1756284818820438]^ Primary outcomes of symptom improvement were usually reported on short, 3 or 4-point Likert scales. Following recommendations from the Cochrane Handbook, these short ordinal outcome results were dichotomized into 'improvement' or 'no improvement' in judging clinical effectiveness.^[@bibr26-1756284818820438]^ Similarly, binary assessment of global symptom improvement is also accepted as an approach for outcome evaluation in IBS trials.^[@bibr39-1756284818820438]^

Since results of all 3-point Likert scales were categorized as 'markedly effective,' 'effective' and 'no improvement' while those of all 4-point Likert scale were categorized as 'clinical remission,' 'markedly effective,' 'effective' and 'no improvement,' the categories of 'clinical remission,' 'markedly effective' or 'effective' results were combined into a category named 'improvement,' while 'no improvement' was labelled as a nonbeneficial category in all analyses.

Literature search {#section11-1756284818820438}
-----------------

A comprehensive literature search for SRs was conducted in eight databases from inception until December 2017. Potential SRs were searched through both international databases (*MEDLINE, EMBASE, Cochrane Database of Systematic Reviews and Database of Abstracts of Reviews of Effect*) and Chinese databases (*Chinese Biomedical Databases, China National Knowledge Infrastructure, Wan Fang Digital Journals and Taiwan Periodical Literature Databases*) without language or publication status restrictions. Specialized search filters for reviews were used in *MEDLINE*^[@bibr40-1756284818820438]^ and *EMBASE*.^[@bibr41-1756284818820438]^ Detailed search strategies are shown in [Appendix 1](#app1-1756284818820438){ref-type="app"}.

Literature selection, data extraction, methodological quality and risk of bias assessment {#section12-1756284818820438}
-----------------------------------------------------------------------------------------

Eligible SRs were selected independently by two researchers (CHLW and WKWC). They conducted data extraction, assessment of methodological quality of eligible SRs and risk of bias of included RCTs independently. Any disagreement was resolved by discussion and consensus between them. Further unresolved discrepancy was managed by a third reviewer (IXYW).

Citations of SRs generated through database searches were screened and assessed for eligibility. Lists of included RCTs were retrieved from eligible SRs. For duplicate or overlapping RCT publications, the single most updated and comprehensive version was chosen. To be included in the NMA, RCTs had to include a common control intervention that provides a bridge for the indirect comparison of different acupuncture interventions.

The following data were extracted from each included RCT: year of publication, source of patients, number of patients enrolled, diagnostic criteria used, duration of IBS diagnosis, patient characteristics, details of interventions, types of outcome assessment, reporting of adverse events, as well as information for assessing risk of bias.

The methodological quality of included SRs was assessed using the AMSTAR instrument,^[@bibr42-1756284818820438]^ which is a reliable and validated tool for conducting appraisal in overviews of SRs.^[@bibr43-1756284818820438]^ In total, 11 aspects were assessed by using AMSTAR according to the information provided. Each aspect was judged as yes, no, cannot answer or not applicable. The risk of bias of each retrieved RCT was assessed with the Cochrane risk of bias tool.^[@bibr44-1756284818820438]^ Overall, six domains in the risk of bias, namely sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessments, incomplete outcome data, and selective outcome reporting, were assessed, with each domain being judged as having low, unclear, or high risk of bias based on the information reported in each RCT publication.

Data synthesis {#section13-1756284818820438}
--------------

In this overview of SR, we followed established methods of conducting pairwise meta-analyses, followed by an NMA, which are considered as standard methodology in the field.^[@bibr45-1756284818820438]^ Pairwise random-effect model meta-analyses were used to synthesize data separately from individual types of acupuncture and related therapies or add-on of acupuncture and related therapies to control treatment, by comparing with identical control treatments.^[@bibr46-1756284818820438]^ For dichotomous data extracted from RCTs, pooled relative risks (RRs) with a 95% confidence interval (CI) were used to quantify the effectiveness of acupuncture and related therapies on IBS symptoms improvement. Heterogeneity across RCTs was tested with a Chi-square test and a *p* value \< 0.1 was considered as an indicator of significant heterogeneity. The level of heterogeneity was measured with the *I*^2^ statistic, with *I*^2^ \<25% regarded as a low level, 25--50% as a moderate level and \>50% as a high level.^[@bibr47-1756284818820438]^

NMA is a preferred approach which offers a set of methods to visualize and interpret the wider picture of existing evidence, as well as to understand the comparative effectiveness of these multiple treatments.^[@bibr48-1756284818820438]^ It provides indirect evidence (comparison between different treatments *via* common comparators) when direct evidence (head-to-head comparison of different treatments) is unavailable.^[@bibr25-1756284818820438]^ It was conducted to explore, relatively speaking, the 'most' effective option for improving IBS symptoms among included interventions. With the common comparator of control interventions, indirect comparisons between different interventions on the effectiveness of IBS symptoms improvement were implemented with the 'mvmeta' command in STATA.^[@bibr49-1756284818820438],[@bibr50-1756284818820438]^

Network geometry was presented to describe the types of treatments in the network of comparisons using a network graph.^[@bibr51-1756284818820438]^ Comparative effectiveness ranking results of all included interventions were summarized from NMA. The probability of each intervention being, relatively, the 'most' effective treatment option, the second-best treatment and so on was deduced. SUCRA, the surface under the cumulative ranking curve,^[@bibr52-1756284818820438]^ is used to provide an effectiveness hierarchy. The larger the SUCRA, the higher effectiveness ranking the treatment would have. This data analysis was conducted using STATA version 13.0.

Consistency of direct evidence and indirect evidence on the same comparison is a key assumption in NMA.^[@bibr50-1756284818820438]^ In this NMA, loop-specific approach was used to assess consistency of each individual closed loop of the network, by comparing direct and indirect estimates of a specific comparison.^[@bibr49-1756284818820438]^ Presence of inconsistency in each loop was measured by the ratio of odds ratios (RoRs) between direct and indirect evidence results in the loop. A RoR value close to 1 indicates that the two evidence sources were consistent,^[@bibr49-1756284818820438]^ and the result was presented in an inconsistency factor (IF) plot. The consistency assessment is implemented using the 'ifplot' command in STATA.^[@bibr49-1756284818820438]^

Sensitivity analysis was carried out by excluding studies of acupuncture plus Chinese herbal medicine and only including studies which explored the effectiveness of needle acupuncture, needle acupuncture plus moxibustion, electroacupuncture, moxibustion and three pharmacological therapies (pinaverium bromide, trimebutine maleate and loperamide) on IBS symptoms improvement.

Results {#section14-1756284818820438}
=======

Results on literature search and selection {#section15-1756284818820438}
------------------------------------------

A total of 15 SRs ([Appendix 2](#app2-1756284818820438){ref-type="app"}) were identified through the literature search and were considered eligible for inclusion in the overview of SRs. These 15 SRs included a total of 180 RCTs. Overall, 153 RCTs were excluded from the NMA due to the following reasons: duplicates (*n* = 65), no IBS symptom-related outcome data reported (*n* = 1), trials with no common comparator with other RCTs for inclusion in the NMA (*n* = 76), trials with different outcome from other RCTs in the NMA (*n* = 10) and overlapping of study population (*n* = 1). Hence, 27 RCTs ([Appendix 3](#app3-1756284818820438){ref-type="app"}) were included in the NMA. Details of the literature search and selection are presented in [Figure 1](#fig1-1756284818820438){ref-type="fig"}.

![Flowchart of literature selection on systematic reviews of acupuncture and related therapies for irritable bowel syndrome.](10.1177_1756284818820438-fig1){#fig1-1756284818820438}

Characteristics of included RCTs {#section16-1756284818820438}
--------------------------------

### Participants {#section17-1756284818820438}

The 27 RCTs included a total of 2141 participants, with sample sizes varying from 40 to 300 patients. The age range of participants was 18--77 years. Duration of IBS ranged from 0.25 years to 38 years. All RCTs were conducted in China among Chinese populations. A total of 13 trials included outpatients only, 11 trials included both inpatients and outpatients and 3 trials did not report the study setting.

### Diagnostic criteria and subtypes of IBS {#section18-1756284818820438}

A total of 24 RCTs recruited IBS patients using Rome/Rome II/Rome III criteria. Among them, 12 conducted patient eligibility assessments with additional diagnostic criteria, including Chinese IBS guidelines or traditional Chinese medicine (TCM) clinical practice guidelines. Overall, 18 recruited patients with IBS-D and 6 did not specify the subtype of IBS. For the remaining three RCTs, two recruited IBS patients using the Chinese IBS guidelines, while one did not specify the diagnostic criteria.

### Interventions {#section19-1756284818820438}

A total of 14 interventions were evaluated in these 27 RCTs, including needle acupuncture (*n* = 12), electroacupuncture (*n* = 5), needle acupuncture plus moxibustion (*n* = 4), moxibustion (*n* = 2), periorbital acupuncture (*n* = 2), catgut embedding (*n* = 1), catgut embedding plus pharmacological therapy (trimebutine maleate) (*n* = 1), needle acupuncture plus Chinese herbal medicine (Geshanxiaoyao formula; *n* = 1), Geshanxiaoyao formula alone (*n* = 1), Chinese herbal medicine (Tongxieyaofang; *n* = 3), *Bifidobacterium* (*n* = 1), and three different pharmacological therapies, including two antispasmodics \[pinaverium bromide (*n* = 15) and trimebutine maleate (*n* = 5)) and an antidiarrheal (loperamide (*n* = 3)\]. Composition of Geshanxiaoyao formula and Tongxieyaofang is listed in [Appendix 4](#table9-1756284818820438){ref-type="table"}. The duration of interventions ranged from 14 to 56 days. All the RCTs assessed global IBS symptom improvement at the end of treatment. Characteristics of included RCTs can be found in [Table 2](#table2-1756284818820438){ref-type="table"}.^[@bibr35-1756284818820438],[@bibr36-1756284818820438],[@bibr53-1756284818820438][@bibr54-1756284818820438][@bibr55-1756284818820438][@bibr56-1756284818820438][@bibr57-1756284818820438][@bibr58-1756284818820438][@bibr59-1756284818820438][@bibr60-1756284818820438][@bibr61-1756284818820438][@bibr62-1756284818820438][@bibr63-1756284818820438][@bibr64-1756284818820438][@bibr65-1756284818820438][@bibr66-1756284818820438][@bibr67-1756284818820438][@bibr68-1756284818820438][@bibr69-1756284818820438][@bibr70-1756284818820438][@bibr71-1756284818820438][@bibr72-1756284818820438][@bibr73-1756284818820438][@bibr74-1756284818820438][@bibr75-1756284818820438][@bibr76-1756284818820438]--[@bibr77-1756284818820438]^

###### 

Main characteristics of included randomized controlled trials.

![](10.1177_1756284818820438-table2)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, country                                    Source of patients         IBS diagnostic criteria, IBS subtype                                             Types of intervention                              Details of intervention\                                                                                      No. of patients\   Age range/ mean ± SD (years)   Length of time since IBS diagnosis\   Types of outcomes assessment                                         Reporting of adverse events
                                                                                                                                                                                                                          (Duration of each session (mins/session), no. of sessions/dosage (on prescription); length of intervention)   (A/R)                                             (range/ mean ± SD)                                                                                         
  -------------------------------------------------------- -------------------------- -------------------------------------------------------------------------------- -------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ------------------ ------------------------------ ------------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------------------------------------
  Xu and colleagues,^[@bibr75-1756284818820438]^ China     Inpatient and outpatient   Chinese IBS guideline, IBS subtype: NR                                           Needle acupuncture plus moxibustion                Acupuncture: 40 mins/session; moxibustion: 30 mins/session;\                                                  31/31              22.0--66.0                     1.00--12.00 years                     Global IBS symptoms improvement assessed on a 4-point Likert scale   NR
                                                                                                                                                                                                                          21 sessions; 21 d                                                                                                                                                                                                                                                          

                                                                                                                                                                       Pinaverium bromide                                 50 mg (t.i.d.); 21 d                                                                                          30/30              25.0--70.0                     1.00--10.00 years                                                                                          

  Sun and colleagues,^[@bibr70-1756284818820438]^ China    Outpatient                 Rome III criteria, IBS-D                                                         Needle acupuncture                                 30 mins/session;\                                                                                             30/31              18.0--61.0                     1.00--20.00 years                     Global IBS symptoms improvement assessed on a 4-point Likert scale   No occurrence of adverse events was observed.
                                                                                                                                                                                                                          20 sessions; 28 d                                                                                                                                                                                                                                                          

                                                                                                                                                                       Pinaverium bromide                                 50 mg (t.i.d.); 28 d                                                                                          30/32              18.0--59.0                     1.00--38.00 years                                                                                          

  Luo and colleagues,^[@bibr66-1756284818820438]^ China    Outpatient                 Rome II criteria & Chinese IBS guideline, IBS-D                                  Moxibustion                                        30 mins/session,\                                                                                             48/48              26.0--63.0                     1.00-- 16.00 years                    Global IBS symptoms improvement assessed on a 3-point Likert scale   NR
                                                                                                                                                                                                                          60 sessions; 30 d                                                                                                                                                                                                                                                          

                                                                                                                                                                       Pinaverium bromide                                 50 mg (t.i.d.); 30 d                                                                                          47/47              24.0--62.0                                                                                                                                

  Liu,^[@bibr64-1756284818820438]^ China                   Outpatient                 Rome III criteria,\                                                              Needle acupuncture                                 Duration of each session: NR; no. of sessions: NR; 28 d                                                       30/30              42.3 ±7.6                      2.51 years\                           Global IBS symptoms improvement assessed on a 4-point Likert scale   NR
                                                                                      IBS-D                                                                                                                                                                                                                                                                                               ±1.28                                                                                                      

                                                                                                                                                                       Pinaverium bromide                                 50 mg (t.i.d.); 28 d                                                                                          30/30              41.8 ± 9.0                     2.48 years\                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                          ±1.32                                                                                                      

  Kong and colleagues,^[@bibr56-1756284818820438]^ China   Outpatient                 Rome III criteria and TCM clinical practice guideline,\                          Needle acupuncture                                 30 mins/ session,\                                                                                            29/30              38.0 ± 11.0                    6.21 years\                           Global IBS symptoms improvement assessed on a 4-point Likert scale   NR
                                                                                      IBS-D                                                                                                                               28 sessions; 28 d                                                                                                                                               ±6.33                                                                                                      

                                                                                                                                                                       Pinaverium bromide                                 50 mg (t.i.d.); 28 d                                                                                          28/30              38.0 ± 11.0                    5.40 years ±\                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                          3.85                                                                                                       

  Wei and colleagues,^[@bibr72-1756284818820438]^\         Outpatient                 Rome II criteria, IBS subtype: NR                                                Needle acupuncture                                 20 mins/ session,\                                                                                            30/30              15.0--66.0                     4.37 years\                           Global IBS symptoms improvement assessed on a 4-point Likert scale   NR
  China                                                                                                                                                                                                                   30 sessions; 30 d                                                                                                                                               (SD: NR)                                                                                                   

                                                                                                                                                                       Pinaverium bromide                                 50 mg (q.d.); 28 d                                                                                            30/30              22.0--77.0                     3.37 years\                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                          (SD: NR)                                                                                                   

  Liu and Wang,^[@bibr61-1756284818820438]^\               Outpatient                 TCM clinical practice guideline,\                                                Electroacupuncture                                 20 mins/ session,\                                                                                            30/30              18.0--60.0                     0.25-- 5.00 years                     Global IBS symptoms improvement assessed on a 3-point Likert scale   NR
  China                                                                               IBS subtype: NR                                                                                                                     24 sessions; 24 d                                                                                                                                                                                                                                                          

                                                                                                                                                                       Pinaverium bromide                                 50 mg (t.i.d.); 20 d                                                                                          30/30                                                                                                                                                        

  Sun and Song,^[@bibr71-1756284818820438]^ China          Inpatient and Outpatient   Rome III criteria and TCM clinical practice guideline,\                          Electroacupuncture                                 30 mins/ session,\                                                                                            30/30              38.0 ± 12.0                    5.16 years ± 4.67                     Global IBS symptoms improvement assessed on a 4-point Likert scale   No occurrence of adverse events was observed.
                                                                                      IBS subtype: NR                                                                                                                     15 sessions; 21 d                                                                                                                                                                                                                                                          

                                                                                                                                                                       Pinaverium bromide                                 50 mg (t.i.d.); 21 d                                                                                          30/30                                                                                                                                                        

  Li and colleagues,^[@bibr57-1756284818820438]^\          Outpatient                 Rome III criteria,\                                                              Electroacupuncture                                 30 mins/ session, 12--14 sessions; 28 d                                                                       35/35              39.1 ± 11.8                    4.33 years\                           Global IBS symptoms improvement assessed on a 4-point Likert scale   NR
  China                                                                               IBS-D                                                                                                                                                                                                                                                                                               ±3.93                                                                                                      

                                                                                                                                                                       Pinaverium bromide                                 50 mg (t.i.d.); 28 d                                                                                          35/35              37.9 ± 11.5                    5.23 years\                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                          ±7.35                                                                                                      

  Li,^[@bibr59-1756284818820438]^ China                    Inpatient and Outpatient   Rome III criteria, TCM clinical practice guideline and Chinese IBS guideline,\   Needle acupuncture                                 30 mins/ session, 20 sessions; 20 d                                                                           30/32              55.5 ± 5.4                     3.65 years\                           Global IBS symptoms improvement assessed on a 4-point Likert scale   NR
                                                                                      IBS subtype: NR                                                                                                                                                                                                                                                                                     ±1.74                                                                                                      

                                                                                                                                                                       Pinaverium bromide                                 50 mg (t.i.d.); 21 d                                                                                          30/32              55.3 ± 5.0                     3.63 years\                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                          ±1.80                                                                                                      

  Li and colleagues,^[@bibr58-1756284818820438]^ China     Inpatient and Outpatient   Rome III criteria and TCM clinical practice guideline,\                          Needle acupuncture                                 30 mins/ session, 28 sessions; 56 d                                                                           30/30              46.0 ± 16.0                    13.60 years ±9.80                     Global IBS symptoms improvement assessed on a 3-point Likert scale   NR
                                                                                      IBS-D                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                       Pinaverium bromide                                 50 mg (t.i.d.); 56 d                                                                                          30/30              44.0 ± 16.0                    13.30 years\                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                          ±10.10                                                                                                     

  Wu and Gao,^[@bibr74-1756284818820438]^ China            Outpatient                 Rome III criteria & Chinese IBS guideline,\                                      Electroacupuncture                                 30 mins/ session, 15 sessions; 30 d                                                                           30/30              25.0--62.0                     NR                                    Global IBS symptoms improvement using binary assessment              NR
                                                                                      IBS subtype: NR                                                                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                       Pinaverium bromide                                 50 mg (t.i.d.); 30 d                                                                                          30/30              27.0--65.0                                                                                                                                

  Pei and colleagues,^[@bibr67-1756284818820438]^ China    Outpatient                 Rome III criteria & TCM clinical practice guideline,\                            Needle acupuncture                                 30 mins/session, 20 sessions; 28 d                                                                            30/33              39.1 ± 11.8                    4.93 years\                           Global IBS symptoms improvement assessed on a 3-point Likert scale   NR
                                                                                      IBS-D                                                                                                                                                                                                                                                                                               ±3.93                                                                                                      

                                                                                                                                                                       Pinaverium bromide                                 50 mg (t.i.d.); 28 d                                                                                          30/32              37.9 ± 11.5                    5.23 years\                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                          ±7.35                                                                                                      

  Gao,^[@bibr35-1756284818820438]^\                        Inpatient and outpatient   Rome III criteria & Chinese IBS guideline, IBS-D                                 Periorbital acupuncture                            15 mins/session, 20 sessions; 20 d                                                                            30/32              37.2 ±10.2                     4.14 years\                           Global IBS symptoms improvement assessed on a 4-point Likert scale   Five cases of bruises were observed in periorbital acupuncture group.
  China                                                                                                                                                                                                                                                                                                                                                                                   ±1.12                                                                                                      

                                                                                                                                                                       Pinaverium bromide                                 50 mg (t.i.d.); 28 d                                                                                          30/32              40.1 ±11.7                     4.13 years\                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                          ±1.76                                                                                                      

  Liu,^[@bibr36-1756284818820438]^ China                   Outpatient                 Rome III criteria and TCM clinical practice guideline,\                          Periorbital acupuncture                            20 mins/ session, 20 sessions; 20 d                                                                           29/30              37.0 ± 10.1                    4.08 years\                           Global IBS symptoms improvement assessed on a 4-point Likert scale   Five cases of bruises were observed in periorbital acupuncture group.
                                                                                      IBS-D                                                                                                                                                                                                                                                                                               ±1.11                                                                                                      

                                                                                                                                                                       Pinaverium bromide                                 50 mg (t.i.d.); 28 d                                                                                          29/30              39.7 ± 10.6                    4.11 years\                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                          ±1.58                                                                                                      

  Zeng and colleagues,^[@bibr77-1756284818820438]^ China   Inpatient and outpatient   Rome criteria, IBS-D                                                             Needle acupuncture plus moxibustion                20 mins/session,\                                                                                             29/33              35.2 ± 7.2                     1.27 years\                           Global IBS symptoms improvement assessed on a 3-point Likert scale   NR
                                                                                                                                                                                                                          30 sessions; 30 d                                                                                                                                               ±7.85                                                                                                      

                                                                                                                                                                       Trimebutine maleate                                100 mg (t.i.d.); 30 d                                                                                         31/32              34.7 ± 6.5                     1.24 years\                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                          ±7.77                                                                                                      

  Shi and colleagues,^[@bibr69-1756284818820438]^ China    Inpatient and outpatient   Rome II criteria, IBS subtype: NR                                                Needle acupuncture                                 30 mins/session,\                                                                                             20/20              43.5 ± 5.3                     0.90 year-5.00 years                  Global IBS symptoms improvement assessed on a 3-point Likert scale   NR
                                                                                                                                                                                                                          28 sessions; 28 d                                                                                                                                                                                                                                                          

                                                                                                                                                                       Trimebutine maleate                                Dosage: NR (t.i.d.); 28d                                                                                      20/20              46.2 ± 4.7                     1.00--4.50 years                                                                                           

  Liu,^[@bibr65-1756284818820438]^\                        NR                         Rome III criteria, IBS-D                                                         Needle acupuncture                                 20 mins/session,\                                                                                             31/31              23.0--64.0                     3.15 years\                           Global IBS symptoms improvement assessed on a 4-point Likert scale   A few cases of nausea and rash were observed in trimebutine maleate group.
  China                                                                                                                                                                                                                   30 sessions; 35 d                                                                                                                                               ± 1.02                                                                                                     

                                                                                                                                                                       Trimebutine maleate                                200 mg (t.i.d.); 35 d                                                                                         31/31              20.0--65.0                     3.52 years\                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                          ± 0.95                                                                                                     

  Shi and colleagues,^[@bibr68-1756284818820438]^ China    Inpatient and outpatient   Rome III criteria, IBS-D                                                         Electroacupuncture                                 30 mins/session,\                                                                                             60/60              40.2 ± 10.8                    8.60 years\                           Global IBS symptoms improvement assessed on a 3-point Likert scale   NR
                                                                                                                                                                                                                          56 sessions; 56 d                                                                                                                                               ± 3.80                                                                                                     

                                                                                                                                                                       Trimebutine maleate                                200 mg (t.i.d.); 56 d                                                                                         60/60              38.5 ± 9.1                     7.30 years\                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                          ± 2.10                                                                                                     

  Yao,^[@bibr76-1756284818820438]^ China                   Outpatient                 Rome III criteria & TCM clinical practice guideline,\                            Catgut embedding plus trimebutine maleate          7 d/session, 2 sessions plus 200 mg (t.i.d.); 14 d                                                            30/30              18.0--65.0                     NR                                    Global IBS symptoms improvement assessed on a 4-point Likert scale   No occurrence of adverse events was observed.
                                                                                      IBS-D                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                       Trimebutine maleate                                200 mg (t.i.d.); 14 d                                                                                         30/30              18.0--65.0                                                                                                                                

  Guo and colleagues,^[@bibr55-1756284818820438]^ China    NR                         Rome II criteria, IBS-D                                                          Needle acupuncture plus moxibustion                30 mins/session,\                                                                                             52/52              18.0--60.0                     1.00--15.00 years                     Global IBS symptoms improvement assessed on a 3-point Likert scale   NR
                                                                                                                                                                                                                          30 sessions; 30 d                                                                                                                                                                                                                                                          

                                                                                                                                                                       Loperamide                                         2 mg (t.i.d.); 30 d                                                                                           48/48              20.0--60.0                     1.00--14.00 years                                                                                          

  Chu and colleagues,^[@bibr53-1756284818820438]^ China    Inpatient & outpatient     Rome II criteria, IBS-D                                                          Moxibustion                                        30 mins/session,\                                                                                             30/30              23.0--61.0                     0.25--\                               Global IBS symptoms improvement assessed on a 4-point Likert scale   NR
                                                                                                                                                                                                                          15 sessions; 15 d                                                                                                                                               4.00 years                                                                                                 

                                                                                                                                                                       Loperamide                                         2 mg (b.i.d.); 15 d                                                                                           30/30              24.0--60.0                     0.25--\                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                          5.00 years                                                                                                 

  Ge and Zeng,^[@bibr54-1756284818820438]^\                NR                         Rome criteria,\                                                                  Needle acupuncture plus moxibustion                30 mins/session,\                                                                                             60/60              38.9 ± 11.2                    1.00--13.00 years                     Global IBS symptoms improvement assessed on a 4-point Likert scale   NR
  China                                                                               IBS subtype: NR                                                                                                                     24 sessions; 28 d                                                                                                                                                                                                                                                          

                                                                                                                                                                       Loperamide                                         2 mg (t.i.d.); 28 d                                                                                           60/60              39.1 ± 10.3                    1.00--12.00 years                                                                                          

  Liu and colleagues,^[@bibr63-1756284818820438]^ China    Inpatient and outpatient   Rome III criteria,\                                                              Needle acupuncture plus Chinese herbal medicine\   Duration of each session: NR, 28 sessions plus 150 mL (b.i.d.); 28 d                                          150/150            45.8 ± 7.9                     2.05 years\                           Global IBS symptoms improvement assessed on a 4-point Likert scale   No occurrence of adverse events was observed.
                                                                                      IBS-D                                                                            (Geshanxiaoyao formula)                                                                                                                                                                                            ±3.10                                                                                                      

                                                                                                                                                                       *Bifidobacterium*                                  Dosage: NR(b.i.d.); 28 d                                                                                      50/50              46.2 ± 8.1                     1.98 years\                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                          ±2.92                                                                                                      

                                                                                                                                                                       Chinese herbal medicine\                           150 mL (b.i.d.); 28 d                                                                                         50/50              45.7 ± 7.9                     2.03 years\                                                                                                
                                                                                                                                                                       (Geshanxiaoyao formula)                                                                                                                                                                                            ±2.84                                                                                                      

                                                                                                                                                                       Needle acupuncture                                 Duration of each session: NR, 28 sessions; 28 d                                                               50/50              46.1 ± 8.1                     2.09 years\                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                          ± 2.89                                                                                                     

  Liu,^[@bibr62-1756284818820438]^ China                   Outpatient                 Rome III criteria & TCM clinical practice guideline,\                            Catgut embedding                                   7d/session, 6 sessions; 42 d                                                                                  30/30              37.0 ± 8.1                     NR                                    Global IBS symptoms improvement assessed on a 4-point Likert scale   Three cases of thickening on the regions where catgut embedding was carried out were observed.
                                                                                      IBS-D                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                       Chinese herbal medicine\                           1 dose/d; 42 d                                                                                                29/30              35.0 ± 8.7                     NR                                                                                                         
                                                                                                                                                                       (Tongxieyaofang)                                                                                                                                                                                                                                                                                                              

  Wen,^[@bibr73-1756284818820438]^ China                   Outpatient                 Rome III criteria & TCM clinical practice guideline,\                            Needle acupuncture                                 20 mins/session,\                                                                                             30/30              18.0--65.0                     NR                                    Global IBS symptoms improvement assessed on a 4-point Likert scale   NR
                                                                                      IBS-D                                                                                                                               15 sessions; length of intervention: NR                                                                                                                                                                                                                                    

                                                                                                                                                                       Chinese herbal medicine\                           2 g (t.i.d.); 28 d                                                                                            30/30              18.0--65.0                                                                                                                                
                                                                                                                                                                       (Tongxieyaofang)                                                                                                                                                                                                                                                                                                              

  Liao,^[@bibr60-1756284818820438]^ China                  Inpatient and outpatient   NR                                                                               Needle acupuncture                                 30 mins/session,\                                                                                             97/97              16.0--58.0                     0.50--28.00 years                     Global IBS symptoms improvement assessed on a 3-point Likert scale   NR
                                                                                                                                                                                                                          10 sessions; length of intervention: NR                                                                                                                                                                                                                                    

                                                                                                                                                                       Chinese herbal medicine\                           1 dose/d; length of intervention: NR                                                                          35/35              22.0--50.0                     0.42--32 years                                                                                             
                                                                                                                                                                       (Tongxieyaofang)                                                                                                                                                                                                                                                                                                              
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A, number of patients analysed; b.i.d., two times a day; d, day; IBS, irritable bowel syndrome; IBS-D, irritable bowel syndrome-diarrhea type; NR, not reported; q.d., once a day; mins, minutes; R, Number of patients randomized; SD, standard deviation; TCM, traditional Chinese medicine; t.i.d., three times a day.

4-point Likert scale ranged from clinically remitted, markedly effective, effective to no improvement; 3-point Likert scale ranged from markedly effective, effective to no improvement; binary assessment included improvement and no improvement.

Methodological quality of included SRs and risk of bias among included RCTs {#section20-1756284818820438}
---------------------------------------------------------------------------

The methodological quality of the 15 SRs was mediocre. A total of 13 (86.7%) SRs performed comprehensive literature searches and assessed and documented scientific quality of the included studies. Overall, 12 (80.0%) SRs provided characteristics of the primary studies and considered the scientific quality of the study results in drawing conclusions. A total of 11 (73.3%) SRs used appropriate methods to combine the findings. Nevertheless, only one (6.67%) SR used the publication status as an inclusion criterion and provided an '*a priori*' design. Details of the methodological quality of included SRs are presented in [Appendix 5](#table10-1756284818820438){ref-type="table"}.

Among the 27 included trials, 16 (59.3%) reported details on sequence generation and used appropriate methods, and thus were judged as having a low risk of bias, while the remaining 11 did not report the procedure of sequence generation clearly. A total of 26 (96.3%) RCTs did not state any details on allocation concealment and were judged as having an unclear risk of bias. Only one (3.7%) trial reported using opaque envelopes to ensure allocation concealment. Only nine (33.3%) trials addressed how incomplete outcomes data were handled, and they were judged as having low risk of bias. All included trials had high risk of bias in blinding of participants and personnel to the intervention assignment, as well as blinding of outcome assessment. All included trials had unclear risk of bias in the domain of selective outcome reporting, as their trial protocols were unavailable. Details of risk of bias are shown in [Table 3](#table3-1756284818820438){ref-type="table"}.

###### 

Risk of bias among 28 included randomized controlled trials.

![](10.1177_1756284818820438-table3)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author                                      Random sequence generation                                                                                                                  Allocation concealment                                               Blinding of participants and personnel                                                                                                                                                                                                                                                                                                                        Blinding of outcome assessment                                                                                                            Incomplete outcome data addressed                                                                 Selective outcome reporting
  ------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- -----------------------------
  Xu and colleagues^[@bibr75-1756284818820438]^     Unclear risk\                                                                                                                               Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Unclear risk: 61 patients were randomized while the author did not mention the follow-up rate.    Unclear risk\
                                                    Quote: 'All 61 patients were randomly and voluntarily divided into two groups.'\                                                            Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to needle acupuncture plus moxibustion group or medication group.                                                                                                                                               Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.                                                                                                     Protocol is not available.
                                                    However, the method of random sequence generation was not stated.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Sun and colleagues^[@bibr70-1756284818820438]^    Low risk\                                                                                                                                   Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Low risk\                                                                                         Unclear risk\
                                                    Quote: 'The 63 patients were assigned by a random number table to two groups.'                                                              Details not stated.                                                  Although the study was a single-blinded randomized control study, the blinded party was not mentioned. Blinding was not possible in the study as participants were either randomized to needle acupuncture group or m**e**dication group.                                                                                                                     Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.   60 out of 63 patients completed the study.\                                                       Protocol is not available.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Drop-out rate: 5.0%                                                                               

  Luo and colleagues^[@bibr66-1756284818820438]^    Unclear risk\                                                                                                                               Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Unclear risk: 95 patients were randomized while the author did not mention the follow-up rate.    Unclear risk\
                                                    Quote: '95 patients were randomly divided into two groups.' Random sequence generation method was not stated.                               Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to moxibustion group or medication group.                                                                                                                                                                       Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.                                                                                                     Protocol is not available.

  Liu^[@bibr64-1756284818820438]^                   Unclear risk\                                                                                                                               Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Unclear risk: 60 patients were randomized while the author did not mention the follow-up rate.    Unclear risk\
                                                    Quote: 'Patients were randomized based on admission sequence.' Random sequence generation method not stated.                                Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to needle acupuncture group or m**e**dication group.                                                                                                                                                            Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.                                                                                                     Protocol is not available.

  Kong and colleagues^[@bibr56-1756284818820438]^   Low risk\                                                                                                                                   Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Low risk: 57 out of 60 patients completed the study.\                                             Unclear risk\
                                                    Quote: 'Patients were randomized using a random number table into two groups.'                                                              Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to needle acupuncture group or medication group.                                                                                                                                                                Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.   Drop-out rate: 5.0%.                                                                              Protocol is not available.

  Wei and colleagues^[@bibr72-1756284818820438]^    Unclear risk\                                                                                                                               Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Unclear risk: 60 patients were randomized while the author did not mention the follow-up rate.    Unclear risk\
                                                    Details not stated.                                                                                                                         Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to needle acupuncture group or medication group.                                                                                                                                                                Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.                                                                                                     Protocol is not available.

  Liu and Wang^[@bibr61-1756284818820438]^          Unclear risk\                                                                                                                               Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Unclear risk: 60 patients were randomized while the author did not mention the follow-up rate.    Unclear risk\
                                                    Quote: 'Patients were randomized into treatment and control group.' Random sequence generation method not stated.                           Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to electroacupuncture group or medication group.                                                                                                                                                                Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.                                                                                                     Protocol is not available.

  Sun and Song^[@bibr71-1756284818820438]^          Low risk\                                                                                                                                   Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Unclear risk: 60 patients were randomized while the author did not mention the follow-up rate.    Unclear risk\
                                                    Quote: '60 patients were randomized using a random number table.'                                                                           Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to electroacupuncture group or medication group.                                                                                                                                                                Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.                                                                                                     Protocol is not available.

  Li and colleagues^[@bibr57-1756284818820438]^     Low risk\                                                                                                                                   Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Unclear risk: 70 patients were randomized while the author did not mention the follow-up rate.    Unclear risk\
                                                    Quote: 'Patients recruited were randomized using a random number table.'                                                                    Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to electroacupuncture group or medication group.                                                                                                                                                                Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.                                                                                                     Protocol is not available.

  Li^[@bibr59-1756284818820438]^                    Unclear risk\                                                                                                                               Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Low risk: 60 out of 64 patients completed the study.\                                             Unclear risk\
                                                    Quote: '64 patients were randomized into treatment and control group.' Random sequence generation method not stated.                        Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to needle acupuncture group or medication group.                                                                                                                                                                Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.   Drop-out rate: 6.3%.                                                                              Protocol is not available.

  Li and colleagues^[@bibr58-1756284818820438]^     Low risk\                                                                                                                                   Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Unclear risk: 60 patients were randomized while the author did not mention the follow-up rate.    Unclear risk\
                                                    Quote: 'Patients recruited were randomized using a random number table.'                                                                    Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to needle acupuncture group or medication group.                                                                                                                                                                Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.                                                                                                     Protocol is not available.

  Wu and Gao^[@bibr74-1756284818820438]^            Unclear risk\                                                                                                                               Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Unclear risk: 60 patients were randomized while the author did not mention the follow-up rate.    Unclear risk\
                                                    Quote: 'Patients were randomized based on admission sequence.' Random sequence generation method not stated.                                Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to electroacupuncture group or medication group.                                                                                                                                                                Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.                                                                                                     Protocol is not available.

  Pei and colleagues^[@bibr67-1756284818820438]^    Low risk\                                                                                                                                   Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Low risk: 60 out of 65 patients completed the study.\                                             Unclear risk\
                                                    Quote: '65 eligible patients were randomized using a random number table.'                                                                  Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to needle acupuncture group or medication group.                                                                                                                                                                Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.   Drop-out rate: 7.7%.                                                                              Protocol is not available.

  Gao^[@bibr35-1756284818820438]^                   Low risk\                                                                                                                                   Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Low risk: 60 out of 64 patients completed the study.\                                             Unclear risk\
                                                    Quote: 'A random number table was used to assign included patients into treatment and control group.'                                       Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to periorbital acupuncture group or medication group.                                                                                                                                                           Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.   Drop-out rate: 6.3%.                                                                              Protocol is not available.

  Liu^[@bibr36-1756284818820438]^                   Unclear risk\                                                                                                                               Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Low risk: 58 out of 60 patients completed the study.\                                             Unclear risk\
                                                    Quote: '60 patients were assigned into treatment and control group with randomized method.' Random sequence generation method not stated.   Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to periorbital acupuncture group or medication group.                                                                                                                                                           Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.   Drop-out rate: 3.3%.                                                                              Protocol is not available.

  Zeng and colleagues^[@bibr77-1756284818820438]^   Low risk\                                                                                                                                   Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Low risk\                                                                                         Unclear risk\
                                                    Quote: 'The 65 patients were assigned by a random number table to two groups.'                                                              Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to needle acupuncture plus moxibustion group or medication group.                                                                                                                                               Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.   61 out of 65 patients completed the study.\                                                       Protocol is not available.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Drop-out rate: 6.2%                                                                               

  Shi and colleagues^[@bibr69-1756284818820438]^    Low risk\                                                                                                                                   Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Unclear risk: 40 patients were randomized while the author did not mention the follow-up rate.    Unclear risk\
                                                    Quote: 'The 40 patients were assigned by simple randomization to two groups.'                                                               Details not stated.                                                  Although the study was a single-blinded randomized control study, the blinded party was not mentioned. Blinding was not possible in the study as participants were either randomized to needle acupuncture group or m**e**dication group.                                                                                                                     Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.                                                                                                     Protocol is not available.

  Liu^[@bibr65-1756284818820438]^                   Unclear risk\                                                                                                                               Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Unclear risk: 62 patients were randomized while the author did not mention the follow-up rate.    Unclear risk\
                                                    Quote: 'Patients were randomized into treatment and control group.' Random sequence generation method not stated.                           Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to needle acupuncture group or medication group.                                                                                                                                                                Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.                                                                                                     Protocol is not available.

  Shi and colleagues^[@bibr68-1756284818820438]^    Low risk\                                                                                                                                   Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Unclear risk: 120 patients were randomized while the author did not mention the follow-up rate.   Unclear risk\
                                                    Quote: 'Blocked randomization and random number table were used to assign 120 patients into treatment and control group.'                   Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to electroacupuncture group or medication group.                                                                                                                                                                Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.                                                                                                     Protocol is not available.

  Yao^[@bibr76-1756284818820438]^                   Low risk\                                                                                                                                   Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Unclear risk: 60 patients were randomized while the author did not mention the follow-up rate.    Unclear risk\
                                                    Quote: 'Patients were randomized using a random number table.'                                                                              Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to catgut embedding plus medication group or medication group.                                                                                                                                                  Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.                                                                                                     Protocol is not available.

  Guo and colleagues^[@bibr55-1756284818820438]^    Unclear risk\                                                                                                                               Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Unclear risk: 100 patients were randomized while the author did not mention the follow-up rate.   Unclear risk\
                                                    Quote: 'The 100 patients were assigned to two groups using a randomized design.' Random sequence generation method not stated.              Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to needle acupuncture plus moxibustion group or medication group.                                                                                                                                               Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.                                                                                                     Protocol is not available.

  Chu and colleagues^[@bibr53-1756284818820438]^    Low risk\                                                                                                                                   Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Unclear risk: 60 patients were randomized while the author did not mention the follow-up rate.    Unclear risk\
                                                    Quote: 'The 60 patients were assigned by a random number table to two groups.'                                                              Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to moxibustion group or medication group.                                                                                                                                                                       Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.                                                                                                     Protocol is not available.

  Ge and Zeng^[@bibr54-1756284818820438]^           Low risk\                                                                                                                                   Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Unclear risk: 120 patients were randomized while the author did not mention the follow-up rate.   Unclear risk\
                                                    Quote: '(Patients were) divided into a warm needling group and a western medicine group by using random digits table method.'               Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to needle acupuncture plus moxibustion group or medication group.                                                                                                                                               Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.                                                                                                     Protocol is not available.

  Liu and colleagues^[@bibr63-1756284818820438]^    Low risk\                                                                                                                                   Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Unclear risk: 300 patients were randomized while the author did not mention the follow-up rate.   Unclear risk\
                                                    Quote: 'The 300 patients were assigned by a random number table to four groups.'                                                            Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to needle acupuncture plus Chinese herbal medicine (Geshanxiaoyao formula) group or *Bifidobacterium* group or Chinese herbal medicine (Geshanxiaoyao formula)-alone group or needle acupuncture alone group.   Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.                                                                                                     Protocol is not available.

  Liu^[@bibr62-1756284818820438]^                   Low risk\                                                                                                                                   Low risk\                                                            High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Low risk: 59 out of 60 patients completed the study.\                                             Unclear risk\
                                                    Quote: 'Randomization was done using a random number table.'                                                                                Quote: 'Random numbers were marked and put into opaque envelopes.'   Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to catgut embedding group or Chinese herbal medicine (Tongxieyaofang) group.                                                                                                                                    Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.   Drop-out rate: 1.7%.                                                                              Protocol is not available.

  Wen^[@bibr73-1756284818820438]^                   Low risk\                                                                                                                                   Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Low risk: All patients completed the study.\                                                      Unclear risk\
                                                    Quote: 'Two groups of patients were divided based on randomization from random number table.'                                               Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to needle acupuncture group or Chinese herbal medicine (Tongxieyaofang) group.                                                                                                                                  Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.   Drop-out rate: 0%.                                                                                Protocol is not available.

  Liao^[@bibr60-1756284818820438]^                  Unclear risk\                                                                                                                               Unclear risk\                                                        High risk\                                                                                                                                                                                                                                                                                                                                                    High risk\                                                                                                                                Unclear risk: 132 patients were randomized while the author did not mention the follow-up rate.   Unclear risk\
                                                    Quote: '132 eligible patients were randomized into treatment and control group.' Random sequence generation method not stated.              Details not stated.                                                  Although the study did not mention blinding of participants and researchers, blinding was not possible as participants were either randomized to needle acupuncture group or Chinese herbal medicine (Tongxieyaofang) group.                                                                                                                                  Blinding of assessors was not mentioned and its impact may be high as global IBS symptoms improvement was a subjective outcome measure.                                                                                                     Protocol is not available.
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IBS, irritable bowel syndrome.

Results of pairwise meta-analyses {#section21-1756284818820438}
---------------------------------

Results from pairwise random-effect meta-analyses showed that needle acupuncture was superior in improving global IBS symptoms, compared with either pinaverium bromide (pooled RR = 1.16; 95% CI: 1.07--1.27, *I*^2^ = 0%, 7 RCTs) or trimebutine maleate (pooled RR = 1.25; 95% CI: 1.05--1.49, *I*^2^ = 0%, 2 RCTs). Electroacupuncture was found to have significantly stronger effects in alleviating global IBS symptoms when compared with pinaverium bromide alone (pooled RR = 1.21; 95% CI: 1.08--1.35, *I*^2^ = 0%, 4 RCTs). Needle acupuncture plus moxibustion was significantly more effective than loperamide in improving global IBS symptoms (pooled RR = 1.29; 95% CI: 1.09--1.52, *I*^2^ = 12%, 2 RCTs). Significant differences in global IBS symptom improvement was not found in the pooled results of the following comparisons: (1) Periorbital acupuncture *versus* pinaverium bromide and (2) Needle acupuncture *versus* Tongxieyaofang. Detailed results are presented in [Table 4](#table4-1756284818820438){ref-type="table"}.

###### 

Pairwise meta-analyses: Effectiveness of acupuncture and related therapies for improving global IBS symptoms.

![](10.1177_1756284818820438-table4)

  Comparison                                                                     No. of studies   No. of patients in treatment group   No. of patients in the control group   Pooled RR[\*\*](#table-fn5-1756284818820438){ref-type="table-fn"} or RR (95% CI)   *p* values   *I*^2^ values                                                                             
  ------------------------------------------------------------------------------ ---------------- ------------------------------------ -------------------------------------- ---------------------------------------------------------------------------------- ------------ ------------------------------------------------------------------------------- --------- -----
  Moxibustion *versus* pinaverium bromide                                        1                44                                   48                                     32                                                                                 47           **1.35 (1.09, 1.67)**                                                           0.006     NA
  Needle acupuncture plus moxibustion *versus* pinaverium bromide                1                28                                   31                                     24                                                                                 30           1.13 (0.91, 1.40)                                                               0.260     NA
  Periorbital acupuncture *versus* pinaverium bromide                            2                48                                   59                                     36                                                                                 59           1.35 (0.79, 2.30)[\*\*](#table-fn5-1756284818820438){ref-type="table-fn"}       0.270     76%
  Electroacupuncture *versus* pinaverium bromide                                 4                114                                  125                                    94                                                                                 125          **1.21 (1.08, 1.35)[\*\*](#table-fn5-1756284818820438){ref-type="table-fn"}**   \<0.001   0%
  Needle acupuncture *versus* pinaverium bromide                                 7                184                                  209                                    153                                                                                208          **1.16 (1.07, 1.27)[\*\*](#table-fn5-1756284818820438){ref-type="table-fn"}**   \<0.001   0%
  Needle acupuncture plus moxibustion *versus* trimebutine maleate               1                27                                   29                                     24                                                                                 31           1.20 (0.97, 1.49)                                                               0.090     NA
  Electroacupuncture *versus* trimebutine maleate                                1                55                                   60                                     44                                                                                 60           **1.25 (1.05, 1.48)**                                                           0.010     NA
  Catgut embedding plus trimebutine maleate *versus* trimebutine maleate         1                27                                   30                                     16                                                                                 30           **1.69 (1.18, 2.41)**                                                           0.004     NA
  Needle acupuncture *versus* trimebutine maleate                                2                48                                   51                                     38                                                                                 51           **1.25 (1.05, 1.49)[\*\*](#table-fn5-1756284818820438){ref-type="table-fn"}**   0.010     0%
  Moxibustion *versus* loperamide                                                1                27                                   30                                     23                                                                                 30           1.17 (0.93, 1.48)                                                               0.170     NA
  Needle acupuncture plus moxibustion *versus* loperamide                        2                97                                   112                                    72                                                                                 108          **1.29 (1.09, 1.52)[\*\*](#table-fn5-1756284818820438){ref-type="table-fn"}**   0.002     12%
  Needle acupuncture plus Geshanxiaoyao formula *versus* Geshanxiaoyao formula   1                135                                  150                                    37                                                                                 50           **1.22 (1.02, 1.45)**                                                           0.030     NA
  Needle acupuncture plus Geshanxiaoyao formula *versus Bifidobacterium*         1                135                                  150                                    34                                                                                 50           **1.32 (1.09, 1.61)**                                                           0.005     NA
  Needle acupuncture *versus* Geshanxiaoyao formula                              1                33                                   50                                     37                                                                                 50           0.89 (0.69, 1.15)                                                               0.380     NA
  Needle acupuncture *versus Bifidobacterium*                                    1                33                                   50                                     34                                                                                 50           0.97 (0.74, 1.28)                                                               0.830     NA
  Catgut embedding *versus* Tongxieyaofang                                       1                25                                   30                                     24                                                                                 29           1.01 (0.80, 1.27)                                                               0.950     NA
  Needle acupuncture *versus* Tongxieyaofang                                     2                124                                  127                                    58                                                                                 65           1.08 (0.97, 1.20)[\*\*](#table-fn5-1756284818820438){ref-type="table-fn"}       0.140     25%

CI, confidence interval; IBS, irritable bowel syndrome; NA, not applicable; RR, risk ratio.

Bold values indicate p \< 0.050.

Results of network meta-analysis {#section22-1756284818820438}
--------------------------------

Comparative effectiveness of the 14 interventions for global IBS symptom improvement was assessed using NMA. The network of comparisons included 1 four-arm trials and 26 two-arm trials ([Table 2](#table2-1756284818820438){ref-type="table"}). Both nodes and edges were weighted according to the number of studies involved in each direct comparison. The size of nodes showed that needle acupuncture was the most common comparator across the studies ([Figure 2](#fig2-1756284818820438){ref-type="fig"}). Indirect comparison results on the dichotomous outcome of global IBS symptom improvement among these 14 treatments is shown in [Figure 3](#fig3-1756284818820438){ref-type="fig"}.

![Network of comparisons in the network meta-analysis.\
The width of the lines represents the proportion of the number of trials for each comparison with the total number of trials and the size of the nodes represents the proportion of the number of randomized patients (sample sizes).\
Acu, needle acupuncture; A&G, needle acupuncture plus Geshanxiaoyao formula; A&M, needle acupuncture plus moxibustion; Bif, *Bifidobacterium*; Cat, catgut embedding; C&T, catgut embedding plus trimebutine maleate; Elect, electroacupuncture; Ges, Geshanxiaoyao formula; Lop, loperamide; Mox, moxibustion; Periorbit, periorbital acupuncture; Pin, pinaverium bromide; Ton, Tongxieyaofang; Tri, trimebutine maleate.](10.1177_1756284818820438-fig2){#fig2-1756284818820438}

![Odds ratio and 95% credibility intervals between 14 different interventions: indirect comparisons from network meta-analysis.\
Results are the ORs and related 95% CIs in the row-defining treatment compared with the ORs in the column-defining treatment. ORs \>1 favor the column-defining treatment, and vice versa. Significant result is in bold and underlined.\
Acu, needle acupuncture; A&G, needle acupuncture plus Geshanxiaoyao formula; A&M, needle acupuncture plus moxibustion; Bif, *Bifidobacterium*; C&T, catgut embedding plus trimebutine maleate; Cat, catgut embedding; CI, credibility interval; Elect, electroacupuncture; Ges, Geshanxiaoyao formula; Lop, loperamide; Mox, moxibustion; OR, odds ratio; Periorbit, periorbital acupuncture; Pin, pinaverium bromide; Ton, Tongxieyaofang; Tri, trimebutine maleate.](10.1177_1756284818820438-fig3){#fig3-1756284818820438}

The cumulative probabilities (SUCRA results) of each included intervention being the relatively 'most' effective option is presented in [Figure 4](#fig4-1756284818820438){ref-type="fig"}. The combination of needle acupuncture and Geshanxiaoyao formula had the highest probability of being the best option for improving global IBS symptoms, followed by catgut embedding plus trimebutine maleate, Geshanxiaoyao formula alone and moxibustion.

![Comparative effectiveness of the 14 different interventions: surface under the cumulative ranking curves (SUCRA) for improving overall symptoms in irritable bowel syndrome patients.\
The *x*-axis represents the possible rank of each treatment (from the first best rank to the worst according to the improvement on overall IBS symptoms.) The *y*-axis indicates the cumulative probability for each treatment to be the best treatment, the second-best treatment, the third best treatment, and so on.\
Acu, needle acupuncture; A&G, needle acupuncture plus Geshanxiaoyao formula; A&M, needle acupuncture plus moxibustion; Bif, *Bifidobacterium*; Cat, catgut embedding; C&T, catgut embedding plus trimebutine maleate; Elect, Electroacupuncture; Ges, Geshanxiaoyao formula; Lop, loperamide; Mox, moxibustion; Periorbit, periorbital acupuncture; Pin, pinaverium bromide; Ton, Tongxieyaofang; Tri, trimebutine maleate.](10.1177_1756284818820438-fig4){#fig4-1756284818820438}

IF plot for assessment of consistency is shown in [Appendix 6](#fig5-1756284818820438){ref-type="fig"}. The direct and indirect evidence in seven out of these eight loops were consistent, as RoRs of these seven loops were close to 1, ranging from 1.000 to 1.532. The RoRs of the remaining one quadratic loop, which included (1) needle acupuncture plus moxibustion, (2) loperamide, (3) moxibustion and (4) pinaverium bromide, was 2.619. This implied that the direct estimate could be around two times as large as the indirect estimate or vice versa.

Sensitivity analysis of the network meta-analysis {#section23-1756284818820438}
-------------------------------------------------

The network of the sensitivity analysis is shown in [Appendix 7](#fig6-1756284818820438){ref-type="fig"}. The sensitivity analysis indicated that moxibustion had the highest probability for improving global IBS symptoms, followed by needle acupuncture plus moxibustion, electroacupuncture and needle acupuncture, while trimebutine maleate had the lowest probability. Detailed SUCRA results are presented in [Appendix 8](#fig7-1756284818820438){ref-type="fig"}.

Adverse effects of acupuncture and related therapies {#section24-1756284818820438}
----------------------------------------------------

A total of 8^[@bibr35-1756284818820438],[@bibr36-1756284818820438],[@bibr62-1756284818820438],[@bibr63-1756284818820438],[@bibr65-1756284818820438],[@bibr70-1756284818820438],[@bibr71-1756284818820438],[@bibr76-1756284818820438]^ out of 27 included RCTs reported adverse effect rates. No serious adverse events associated with acupuncture and related therapies were reported. Bruises were observed in periorbital acupuncture group (*n* = 5) in two RCTs.^[@bibr35-1756284818820438],[@bibr36-1756284818820438]^ Thickening in the area where catgut embedding was carried out (*n* = 3) was reported in one RCT.^[@bibr62-1756284818820438]^ All of these events resolved in 3--5 days and participants continued to receive the treatment. A few cases of nausea and rash were reported in trimebutine maleate group in one RCT.^[@bibr65-1756284818820438]^ No occurrence of adverse events was observed in remaining four RCTs.^[@bibr63-1756284818820438],[@bibr70-1756284818820438],[@bibr71-1756284818820438],[@bibr76-1756284818820438]^

Discussion {#section25-1756284818820438}
==========

In this overview, among the 24 RCTs which recruited IBS patients using various version of the Rome diagnostic criteria, of which 17 adopted Rome III. Rome III has been commonly used as one of the IBS diagnostic criteria since it was introduced in 2006. With increasing IBS knowledge in the past decade, it was modified to the latest Rome IV criteria.^[@bibr78-1756284818820438]^ One of the major differences between Rome III and Rome IV criteria is that the frequency of recurrent abdominal pain increased from 3 days per month to 1 day per week on average.^[@bibr79-1756284818820438]^ A recent study conducted by Vork and colleagues suggested that Rome IV IBS patients was likely a subgroup of Rome III IBS patients with more severe symptoms.^[@bibr80-1756284818820438]^ Hence, results from our study may not be directly applicable to IBS patients diagnosed with Rome IV criteria. Future trials might investigate the effect of acupuncture and related therapies for Rome IV IBS patients.

According to the NICE guideline,^[@bibr6-1756284818820438]^ acupuncture is not recommended for treating IBS, due to limited evidence for its effectiveness. Pairwise meta-analyses results from our study indicated that needle acupuncture, electroacupuncture and needle acupuncture plus moxibustion were significantly more effective in alleviating global IBS symptoms when compared with antispasmodics and loperamide, which are pharmacological treatments suggested in the NICE guideline. Even in our NMA sensitivity analysis, the results indicated that moxibustion had the highest probability for improving global IBS symptoms while trimebutine maleate alone had the lowest probability. These results might add to the emerging evidence base on the effectiveness of acupuncture and related therapies for IBS.

In Chinese medicine practice, acupuncture and related therapies are frequently used in conjunction with Chinese herbal medicine, and this combined treatment is generally assumed to provide better treatment effects.^[@bibr81-1756284818820438],[@bibr82-1756284818820438]^ NMA results suggested that the combination of needle acupuncture with Geshanxiaoyao formula had the highest probability being the best treatment option for improving global IBS symptoms. This reconfirmed the multimodal approach adopted in traditional practice. However, since Chinese herbal medicine was not a main focus in this overview, future SRs should comprehensively assess the combined effect of acupuncture and Chinese herbal medicine.

Concurring with previous overviews on acupuncture safety,^[@bibr83-1756284818820438]^ no serious adverse events associated with acupuncture and related therapies were reported among the included studies. Taking into account potential adverse effects of these pharmacological therapies, including dry eyes and mouth from antispasmodics,^[@bibr8-1756284818820438]^ dizziness and vomiting from antidiarrheals,^[@bibr9-1756284818820438]^ IBS patients who are intolerant of these adverse effects may consider using acupuncture and related therapies as alternatives. Nevertheless, since all included RCTs were conducted in China among Chinese populations, generalizability of our results among different populations and geographical locations should be considered.

Limitations and recommendations for research {#section26-1756284818820438}
--------------------------------------------

Firstly, antidepressants are suggested as the second-line treatment for IBS,^[@bibr6-1756284818820438]^ but in this overview we did not locate any trials evaluating the comparative effectiveness of antidepressants and acupuncture, or the potential of using acupuncture as an add-on to antidepressants. These comparisons should be a priority for future trials.

Secondly, the methodological quality of included SRs was assessed as mediocre. The majority of the included reviews performed a comprehensive literature search and included characteristics of primary studies. Most of them also applied appropriate method to combine findings. However, there was still room for improvement, especially in the domains including grey literature and publishing SR protocols. In future, the reporting standards of SRs should follow the PRISMA requirement.^[@bibr84-1756284818820438]^

Thirdly, due to poor reporting, most of the included RCTs are regarded as having an unclear risk of bias in the domains of allocation concealment and selective outcome reporting. This may possibly reduce the trustworthiness of our conclusions. To improve the usefulness of study results, future trials should adhere to the CONSORT reporting statement.^[@bibr85-1756284818820438]^

Fourthly, the primary outcome of this study was subjective global IBS symptom improvement but blinding of patients and investigators were not performed in all included RCTs. This risk of bias may introduce further uncertainty to our conclusion.^[@bibr86-1756284818820438]^ In addition, a more comprehensive assessment on patient-centered outcomes should be added in future pragmatic trials. Additional outcomes including the Bristol stool form scale,^[@bibr87-1756284818820438]^ individual symptom assessment and IBS quality of life questionnaires,^[@bibr88-1756284818820438]^ should be considered.

Lastly, the follow-up duration of all included RCTs ranged from 2 to 7 weeks. Longer term effects of acupuncture and related therapies should be evaluated in future trials, for instance at 12 and 24 weeks of follow up.^[@bibr89-1756284818820438],[@bibr90-1756284818820438]^ Close monitoring and adequate reporting of all adverse events also needs to be considered by future investigators in this field.

Conclusion {#section27-1756284818820438}
==========

In this overview of SRs and NMA, the combination of needle acupuncture and Geshanxiaoyao formula is suggested to have the highest probability of being the most effective treatment for improving global IBS symptoms. In sensitivity analysis where the combined use of acupuncture and Chinese herbal medicine was excluded, moxibustion showed the highest probability of being the most effective treatment for improving global IBS symptoms. However, trustworthiness of this conclusion is limited by lack of blinding and allocation concealment, possible selective outcome reporting. In view of such limitation, (1) needle acupuncture plus Geshanxiaoyao formula and (2) moxibustion could be alternative to those who are not responsive to first-line conventional therapies, or intolerant of the adverse effects of pharmacological treatments.
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1.  (i) EMBASE from inception to 12 December 2017

![](10.1177_1756284818820438-table5)

  ---- ---------------------------------------------------------------------------- -----------
  1    meta-analys:.mp.                                                             223,628
  2    search:.tw.                                                                  453,738
  3    review.pt.                                                                   2,346,395
  4    1 or 2 or 3                                                                  2,774,132
  5    exp irritable bowel syndrome/                                                22,094
  6    irritable bowel syndrome\$.mp.                                               17,919
  7    irritable colon.mp.                                                          22,245
  8    gastrointestinal disease\$.mp.                                               91,777
  9    gastrointestinal syndrome\$.mp.                                              311
  10   Colonic Disease\$.mp.                                                        2019
  11   colon disease\$.mp.                                                          10,873
  12   ((irritable or functional or spastic) and (bowel or colon)).mp.              45,584
  13   5 or 6 or 7 or 8 or 9 or 10 or 11 or 12                                      143,852
  14   exp Acupuncture/                                                             41,273
  15   acupunctur\*.mp.                                                             40,752
  16   exp Acupuncture Points/                                                      41,273
  17   exp Acupuncture Therapy/                                                     41,273
  18   exp Acupuncture Analgesia/                                                   1522
  19   exp Electroacupuncture/                                                      5565
  20   electroacupunctur\*.mp.                                                      6387
  21   electro-acupunctur\*.mp.                                                     1111
  22   acupoint\*.mp.                                                               5280
  23   exp Transcutaneous Electric Nerve Stimulation/                               714
  24   Transcutaneous Electric Nerve Stimulat\*.mp.                                 343
  25   percutaneous electrical nerve stimulat\*.mp.                                 73
  26   TENS.mp.                                                                     13,275
  27   14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26   57,051
  28   4 and 13 and 27                                                              277
  ---- ---------------------------------------------------------------------------- -----------

1.  (ii) MEDLINE from inception to 12 December 2017

![](10.1177_1756284818820438-table6)

  ---- ---------------------------------------------------------------------------- -----------
  1    meta analysis.mp,pt.                                                         133,692
  2    review.pt.                                                                   2,432,940
  3    search:.tw.                                                                  333,880
  4    1 or 2 or 3                                                                  2,667,117
  5    exp irritable bowel syndrome/                                                6669
  6    irritable bowel syndrome\$.mp.                                               11,697
  7    gastrointestinal disease\$.mp.                                               43,831
  8    gastrointestinal syndrome\$.mp.                                              232
  9    Colonic Disease\$.mp.                                                        21,643
  10   colon disease\$.mp.                                                          700
  11   ((irritable or functional or spastic) and (bowel or colon)).mp.              24,753
  12   irritable colon.mp.                                                          463
  13   5 or 6 or 7 or 8 or 9 or 10 or 11 or 12                                      85,118
  14   exp Acupuncture/                                                             1591
  15   acupunctur\*.mp.                                                             23,250
  16   exp Acupuncture Points/                                                      5610
  17   exp Acupuncture Therapy/                                                     21,989
  18   exp Acupuncture Analgesia/                                                   1181
  19   exp Electroacupuncture/                                                      3420
  20   electroacupunctur\*.mp.                                                      4135
  21   electro-acupunctur\*.mp.                                                     713
  22   acupoint\*.mp.                                                               3669
  23   exp Transcutaneous Electric Nerve Stimulation/                               7758
  24   Transcutaneous Electric Nerve Stimulat\*.mp.                                 4459
  25   percutaneous electrical nerve stimulat\*.mp.                                 47
  26   TENS.mp.                                                                     9735
  27   14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26   37,574
  28   4 and 13 and 27                                                              90
  ---- ---------------------------------------------------------------------------- -----------

1.  (iii) Cochrane Database of Systematic Reviews (CDSR) from inception to 12 December 2017

![](10.1177_1756284818820438-table7)

  ---- --------------------------------------------------------------------------------------------------------------------------- -----
  1    irritable bowel syndrome.mp. \[mp=title, abstract, full text, keywords, caption text\]                                      83
  2    irritable bowel syndrome\$.mp. \[mp=title, abstract, full text, keywords, caption text\]                                    85
  3    irritable colon.mp. \[mp=title, abstract, full text, keywords, caption text\]                                               10
  4    gastrointestinal disease\$.mp. \[mp=title, abstract, full text, keywords, caption text\]                                    79
  5    gastrointestinal syndrome\$.mp. \[mp=title, abstract, full text, keywords, caption text\]                                   5
  6    colonic disease\$.mp. \[mp=title, abstract, full text, keywords, caption text\]                                             35
  7    colon disease\$.mp. \[mp=title, abstract, full text, keywords, caption text\]                                               9
  8    ((irritable or functional or spastic) and (bowel or colon)).mp. \[mp=title, abstract, full text, keywords, caption text\]   360
  9    1 or 2 or 3 or 4 or 5 or 6 or 7 or 8                                                                                        436
  10   Acupuncture.mp. \[mp=title, abstract, full text, keywords, caption text\]                                                   482
  11   acupunctur\*.mp. \[mp=title, abstract, full text, keywords, caption text\]                                                  483
  12   Acupuncture Points.mp. \[mp=title, abstract, full text, keywords, caption text\]                                            88
  13   Acupuncture Therapy.mp. \[mp=title, abstract, full text, keywords, caption text\]                                           91
  14   Acupuncture Analgesia.mp. \[mp=title, abstract, full text, keywords, caption text\]                                         23
  15   Electroacupuncture.mp. \[mp=title, abstract, full text, keywords, caption text\]                                            84
  16   electroacupunctur\*.mp. \[mp=title, abstract, full text, keywords, caption text\]                                           87
  17   electro-acupunctur\*.mp. \[mp=title, abstract, full text, keywords, caption text\]                                          58
  18   acupoint\*.mp. \[mp=title, abstract, full text, keywords, caption text\]                                                    63
  19   Transcutaneous Electric Nerve Stimulation.mp. \[mp=title, abstract, full text, keywords, caption text\]                     52
  20   Transcutaneous Electric Nerve Stimulat\*.mp.                                                                                52
  21   percutaneous electrical nerve stimulat\*.mp. \[mp=title, abstract, full text, keywords, caption text\]                      6
  22   TENS.mp.                                                                                                                    162
  23   10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22                                                  563
  24   9 and 23                                                                                                                    44
  ---- --------------------------------------------------------------------------------------------------------------------------- -----

1.  (iv) Database of Abstracts of Reviews of Effects (DARE) from inception to 12 December 2017

![](10.1177_1756284818820438-table8)

  ---- --------------------------------------------------------------------------------- -----
  1    irritable bowel syndrome.mp. \[mp=title, full text, keywords\]                    110
  2    irritable bowel syndrome\$.mp. \[mp=title, full text, keywords\]                  110
  3    irritable colon.mp. \[mp=title, full text, keywords\]                             0
  4    gastrointestinal disease\$.mp.                                                    85
  5    gastrointestinal syndrome\$.mp.                                                   0
  6    colonic disease\$.mp. \[mp=title, full text, keywords\]                           51
  7    colon disease\$.mp. \[mp=title, full text, keywords\]                             0
  8    ((irritable or functional or spastic) and (bowel or colon)).mp.                   152
  9    1 or 2 or 3 or 4 or 5 or 6 or 7 or 8                                              261
  10   Acupuncture.mp. \[mp=title, full text, keywords\]                                 471
  11   acupunctur\*.mp. \[mp=title, full text, keywords\]                                471
  12   Acupuncture Points.mp. \[mp=title, full text, keywords\]                          77
  13   Acupuncture Therapy.mp. \[mp=title, full text, keywords\]                         312
  14   Acupuncture Analgesia.mp. \[mp=title, full text, keywords\]                       31
  15   Electroacupuncture.mp. \[mp=title, full text, keywords\]                          56
  16   electroacupunctur\*.mp. \[mp=title, full text, keywords\]                         56
  17   electro-acupunctur\*.mp. \[mp=title, full text, keywords\]                        26
  18   acupoint\*.mp. \[mp=title, full text, keywords\]                                  47
  19   Transcutaneous Electric Nerve Stimulation.mp. \[mp=title, full text, keywords\]   52
  20   Transcutaneous Electric Nerve Stimulat\*.mp. \[mp=title, full text, keywords\]    52
  21   percutaneous electrical nerve stimulat\*.mp. \[mp=title, full text, keywords\]    1
  22   TENS.mp.                                                                          58
  23   10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22        533
  24   9 and 23                                                                          7
  ---- --------------------------------------------------------------------------------- -----

1.  (v) Wan Fang Digital Journals \[Chinese\] from inception to 12 December 2017

2.  ('系统综述' OR '荟萃分析' OR 'META') AND ('针灸' OR '针刺' OR '电针' OR '耳针' OR '头针' OR '水针') AND ('肠易激综合症' OR 'IBS') 7

3.  (vi) China National Knowledge Infrastructure \[Chinese\] from inception to 12 December 2017

4.  (KY='系统综述' OR KY='荟萃分析' OR KY='META') AND (KY='肠易激综合症' OR KY='IBS') 9

5.  (vii)  Taiwan Periodical Literature Databases \[Chinese\] from inception to 12 December 2017

6.  (TX=系統綜述 OR 薈萃分析 OR META) \[AND\] (TX=針灸 OR 針刺 OR 電針 OR 耳針 OR 頭針 OR 水針) \[AND\] (TX=腸易激綜合症 OR IBS) 3

7.  (viii) Chinese Biomedical Database (CBM) \[Chinese\] from inception to 12 December 2017

8.  ('系统综述'\[全字段\] OR '荟萃分析'\[全字段\] OR 'META'\[全字段\]) AND ('针灸

9.  '\[全字段\]) AND ('肠易激综合症' \[全字段\] OR 'IBS' \[全字段\]) 6

###### 

Composition of Geshanxiaoyao formula and Tongxieyaofang.

![](10.1177_1756284818820438-table9)

  ----------------------------------------------------------------------------------------
  Geshanxiaoyao formula                         Tongxieyaofang
  --------------------------------------------- ------------------------------------------
  \(1\) Cynanchum wilfordii (Maxim.)\           1) Atractylodes macrocephala Koidz.\
    Hook.f. \[Ge Shan Xiao\]                      \[Bai Zhu\]

  \(2\) Bupleurum chinense DC.\                 2) Paeonia lactiflora Pall. \[Bai Shao\]
    \[Chai Hu\]                                 

  \(3\) Paeonia lactiflora Pall. \[Bai Shao\]   3) Saposhnikovia divaricata (Turcz.)\
                                                  Schischk. \[Fang Feng\]

  \(4\) Angelica sinensis (Oliv.) Diels\        4) Citrus aurantium L. \[Chen Pi\]
    \[Dan Gui\]                                 

  \(5\) Smilax glabra Roxb. \[Fu Ling\]         

  \(6\) Atractylodes macrocephala Koidz.\       
    \[Bai Zhu\]                                 

  \(7\) Albizia julibrissin Durazz.\            
    \[He Huan Hua/ He Huan Pi\]                 

  \(8\) Polygonum multiflorum Thunb.\           
    \[Ye Jiao Teng\]                            
  ----------------------------------------------------------------------------------------

Source: Medicinal Plant Names Services. Kew Royal Botanic Gardens (<http://mpns.kew.org/mpns-portal/searchName>).

###### 

Methodological quality of included systematic reviews on acupuncture and related therapies for irritable bowel syndrome.

![](10.1177_1756284818820438-table10)

  First author                                          AMSTAR item                                                                                                           
  ----------------------------------------------------- ------------- ---------- ----------- ---------- ---------- ----------- ----------- ----------- ----------- ---------- ----------
  Manheimer and colleagues^[@bibr1-1756284818820438]^   N             Y          Y           N          N          Y           Y           Y           Y           N          Y
  Suen and Zhong^[@bibr2-1756284818820438]^             N             Y          Y           Y          Y          Y           Y           N           Y           N          N
  Hussain and Quigley^[@bibr3-1756284818820438]^        N             NR         N           N          N          N           N           N           N/A         N          Y
  Park and colleagues^[@bibr4-1756284818820438]^        N             Y          Y           N          N          Y           Y           Y           Y           Y          Y
  Schneider and colleagues^[@bibr5-1756284818820438]^   N             NR         N           N          N          Y           Y           Y           N/A         N          N
  Zhao and colleagues^[@bibr6-1756284818820438]^        N             NR         Y           N          N          N           Y           Y           Y           Y          N
  Pei and colleagues^[@bibr7-1756284818820438]^         N             Y          Y           N          N          Y           Y           Y           Y           N          N
  Lim and colleagues^[@bibr8-1756284818820438]^         Y             Y          Y           N          Y          Y           Y           Y           Y           N          Y
  Chao and Zhang^[@bibr9-1756284818820438]^             N             Y          Y           N          N          Y           Y           Y           Y           N          N
  Chey and colleagues^[@bibr10-1756284818820438]^       N             NR         Y           N          N          N           Y           Y           N/A         N          Y
  Grundmann and Yoon^[@bibr11-1756284818820438]^        N             NR         Y           N          N          Y           N           N           N/A         N          N
  Li and colleagues^[@bibr12-1756284818820438]^         N             NR         Y           N          N          Y           Y           Y           Y           Y          N
  Liu and Chen^[@bibr13-1756284818820438]^              N             NR         Y           N          N          Y           Y           Y           Y           N          Y
  Deng and colleagues^[@bibr14-1756284818820438]^       N             N          Y           N          N          Y           Y           Y           Y           Y          N
  Xu and colleagues^[@bibr15-1756284818820438]^         N             NR         Y           N          N          Y           Y           Y           Y           N          N
  \# of yes (%)                                         1 (6.67)      6 (40.0)   13 (86.7)   1 (6.67)   2 (13.3)   12 (80.0)   13 (86.7)   12 (80.0)   11 (73.3)   4 (26.7)   6 (40.0)

\# of yes, number of yes; N/A, not applicable; N, no; NR, not reported; SR, systematic review; Y, yes (SR fulfilling the criteria);

AMSTAR item: (1). Was an '*a priori*' design provided? (2). Was there duplicate study selection and data extraction? (3). Was a comprehensive literature search performed? (4). Was the status of publication (i.e. grey literature) used as an inclusion criterion? (5). Was a list of studies (included and excluded) provided? (6). Were the characteristics of the included studies provided? (7). Was the scientific quality of the included studies assessed and documented? (8). Was the scientific quality of the included studies used appropriately in formulating conclusions? (9). Were the methods used to combine the findings of studies appropriate? (10). Was the likelihood of publication bias assessed? (11). Was the conflict of interest included?

![IF plot for the network meta-analysis.\
Acu, needle acupuncture; A&G, needle acupuncture plus Geshanxiaoyao formula; A&M, needle acupuncture plus moxibustion; Bif, *Bifidobacterium*; Elect, electroacupuncture; Ges, Geshanxiaoyao formula; Lop, loperamide; Mox, moxibustion; Pin, pinaverium bromide; Tri, trimebutine maleate.](10.1177_1756284818820438-fig5){#fig5-1756284818820438}

![Sensitivity analysis: Network of comparisons including four acupuncture and related therapies and three pharmacological treatments.\
Acu, needle acupuncture; A&M, needle acupuncture plus moxibustion; Elect, electroacupuncture; Lop, loperamide; Mox, moxibustion; Pin, pinaverium bromide; Tri, trimebutine maleate.](10.1177_1756284818820438-fig6){#fig6-1756284818820438}

![Sensitivity analysis: SUCRA for NMA including four acupuncture and related therapies and three pharmacological treatments.\
Acu, needle acupuncture; A&M, needle acupuncture plus moxibustion; Elect, electroacupuncture; Lop, loperamide; Mox, moxibustion; NMA, network meta-analysis; Pin, pinaverium bromide; SUCRA, surface under the cumulative ranking curves; Tri, trimebutine maleate.](10.1177_1756284818820438-fig7){#fig7-1756284818820438}
